17.74 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Avalo Therapeutics, Inc. Common Stock
AVTXNASDAQ • USD
17.69
↘ 0.06 (0.31%)
POST MARKET (AS OF 07:10 PM EDT)
Post Market
AS OF 07:10 PM EDT
17.69
↘ 0.06 (0.31%)
Market: CLOSED
Open?$18.76
High?$19.00
Low?$17.41
Prev. Close?$17.74
Volume?1.5M
Avg. Volume?2.0M
VWAP?$17.98
Rel. Volume?0.77x
Bid / Ask
Bid?$17.40 × 100
Ask?$18.00 × 100
Spread?$0.60
Midpoint?$17.70
Valuation & Ratios
Market Cap?932.5M
Shares Out?52.6M
Float?21.2M
Float %?86.6%
P/E Ratio?N/A
P/B Ratio?13.65
EPS?-$1.61
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Employees
33
Market Cap
932.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-11-13
Address
1500 LIBERTY RIDGE DRIVE
WAYNE, PA 19087
Phone: 410-522-8707
WAYNE, PA 19087
Phone: 410-522-8707
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?7.65Strong
Quick Ratio?7.65Strong
Cash Ratio?2.15Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUED
Score50/100
P/E?N/A▾
P/B?13.65HIGH▾
P/S?15,805.31HIGH▾
P/FCF?N/A▾
EV/EBITDA?-11.5CHEAP▾
EV/Sales?15,381.78HIGH▾
Returns & Efficiency
ROE?-124.0%WEAK▾
ROA?-84.8%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$907.5M
Fundamentals ratios updated end of day